Mikael Dolsten, M.D., Ph.D., ⁠told Fierce Biotech back in February that his professional approach is to be "open to change." Now, after 15 years at Pfizer, including a career-defining pandemic ...

Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down. By Matthew Herper July 9, 2024. Reprints. Mikael Dolsten (center), Pfizer's outgoing head of R&D, is seen at ...

Dolsten, aged 65, served as the head of Pfizer's research and development after he joined the company through its $68 billion acquisition of Wyeth in 2009. During his tenure, Comirnaty — jointly ...

Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor.

US pharmaceutical giant Pfizer announced on Tuesday that its chief scientific officer, Mikael Dolsten, will step down. Dolsten, who played a crucial role in the development of Pfizer's Covid-19 ...

Pfizer CEO Albert Bourla underscored Dolsten’s profound impact on the industry in a company press release and heralded his commitment to a smooth transition process for his successor. “I want to thank ...

Mikael Dolsten’s plans to leave Pfizer, after 15 years helming its research and development, leaves a big hole at the drugmaker as it counts on its pipeline to furnish new sources of sales growth.

Pfizer said on Tuesday Chief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.

US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's Covid-19 vaccine, would step down. Dolsten will be ...

Dolsten, aged 65, served as the head of Pfizer's research and development after he joined the company through its $68 billion acquisition of Wyeth in 2009. During his tenure, Comirnaty — jointly ...

Reuters. FILE PHOTO: Pfizer worldwide research and development president Mikael Dolsten leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014.